


Supplementary Figure 2: MRI lesion activity by age cohort



MRI lesion activity by age cohort. Results stratified by patient age at core study baseline over 8 years. Alemtuzumab treatment was assessed through Year 8, and SC IFNB-1a treatment was assessed only through Year 2 of the core study. (A) Percentages of patients free of new Gd-enhancing T1 lesions in Year 2 of the core study in alemtuzumab- and SC IFNB-1a–treated patients, and in Year 8 of the extensions in alemtuzumab-treated patients. (B) Percentages of patients free of new/enlarging T2 hyperintense lesions in Year 2 of the core study in alemtuzumab- and SC IFNB-1a–treated patients, and in Year 8 of the extensions in alemtuzumab-treated patients. OR for alemtuzumab vs SC IFNB-1a at Year 2 MRI analyses are based on logistic regressions with covariate adjustment for core study baseline. CI, confidence interval; Gd, gadolinium; MRI, magnetic resonance imaging; NE, not estimable; No., number; OR, odds ratio; SC IFNB-1a, subcutaneous interferon beta-1a; Y, year.